Changes in Beneficial Ownership · 4
Perspective Therapeutics, Inc.
CATXNYSE_AMERICANEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-08-31
- Issuer
- Perspective Therapeutics, Inc.
- Issuer CIK
- 0000728387
- Trading symbol
- CATX
Reporting owner 1
- Name
- Lantheus Holdings, Inc.
- Reporting owner CIK
- 0001521036
- Relationship
- 10% owner
- Address
- 201 BURLINGTON ROAD, SOUTH BUILDING, BEDFORD, MA, 01730
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-31 | S · Form 4 | 78,145[F1] | D | 3.143[F2] | 11,599,194[F1] | D[F3] |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.↩ 1↩ 2
- F2
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.095 to $3.165, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.↩ 1
- F3
- Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned direct subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.↩ 1
Signature 1
- Signed
- /s/ Eric M. Green, Vice President, Deputy General Counsel and Assistant Corporate Secretary
- Date
- 2026-09-02
Company context
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, creating an opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.